Wednesday, September 16, 2015

President Obama Makes An Excellent Choice -- To Lead FDA


We have long admired Dr. Califf (as the 2009-vintage graphic at right will attest). Overnight, our 44th President tapped him to lead the FDA -- where he's been serving as Deputy Commissioner, since Spring.

He is smart, fair, balanced and open minded. In short, a great pick. From the White House presser then:

. . . .President Obama announced his intent to nominate the following individuals to key Administration posts:

Dr. Rob Califf, Nominee for Commissioner of Food and Drugs, Department of Health and Human Services

Dr. Rob Califf is Deputy Commissioner for Medical Products and Tobacco at the Food and Drug Administration (FDA), a position he has held since March 2015. Dr. Califf has served in various capacities at Duke University School of Medicine and the Duke University Medical Center between 1982 and 2015. At Duke University School of Medicine, he served as Vice Chancellor, Director of the Duke Translational Medicine Institute, which he founded in 2006, and as Professor of Medicine. He also served as the Director of the Cardiac Care Unit at the Duke University Medical Center. He founded the Duke University Clinical Research Institute in 2006 and served as its Director. Dr. Califf also served on the Executive Committee of the Duke Health System. He has served in a number professional organizations, including committees of the Institute of Medicine of the National Academies (IOM), the IOM Clinical Research Roundtable, the IOM Committee on Medication Errors, and the IOM Board on Health Sciences Policy. He served on the FDA’s Cardio renal Advisory Committee from 1996 to 2000 and on the FDA’s Science Board Working Group from 2007 to 2008. Dr. Califf received a B.S. and an M.D. from Duke University. . . .


Onward, on a truly flawless morning.

1 comment:

Anonymous said...

The FDA is already rubber-stamping 96% of all drug applications ... it's basically a branch of Big Pharma. Now this?

http://www.mintpressnews.com/obamas-new-appointee-to-head-the-fda-is-a-big-pharma-mega-lobbyist/210458/